ZLAB Zai Lab Limited

25.96
+0.26  (+1%)
Previous Close 25.7
Open 25.79
Price To Book 6.61
Market Cap 1313729242
Shares 50,605,903
Volume 171,324
Short Ratio
Av. Daily Volume 155,397

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released August 24, 2018. Primary endpoint not met.
Fugan (ZL-3101)
Eczema
Phase 2 interim data released September 2018.
ZL-2301
Second-line Hepatocellular carcinoma (HCC)
Phase 3 dosing initiated - noted June 29. 2018.
ZL-2306 (niraparib)
First-line maintenance therapy for platinum-responsive ovarian cancer
China NDA filing announced December 12, 2018.
ZL-2306 (niraparib)
Recurrent platinum-sensitive ovarian cancer
Phase 3 portion of Phase 1/3 trial has been initiated - September 10, 2018. Phase 1 data presented at ASCO GI January 17, 2019 noted 19% ORR.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 3 trial initiation announced August 28, 2018.
ZL-2306 (niraparib)
Small cell lung cancer